CHATHAM, NJ—Pharmaceutical companies will need to lower their asset price expectations as they bail out of unneeded office and research facilities, Jeffrey Garibaldi, president of the Garibaldi Group, a leading New Jersey developer, tells GlobeSt.com exclusively.

Echoing comments GlobeSt.com reported yesterday by James W. Hughes, dean of the Edward J. Bloustein School of Planning and Public Policy at Rutgers University, Garibaldi tells GlobeSt.com that “The challenge Big Pharma faces today is that pharma doesn’t operate in major research campuses like the ones built over the past 50 years.”

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2024 ALM Global, LLC. All Rights Reserved.